NasdaqGM:AXSM

Stock Analysis Report

Executive Summary

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Axsome Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.8%

AXSM

-0.1%

US Pharmaceuticals

1.3%

US Market


1 Year Return

426.3%

AXSM

-6.6%

US Pharmaceuticals

5.9%

US Market

Return vs Industry: AXSM exceeded the US Pharmaceuticals industry which returned -6.6% over the past year.

Return vs Market: AXSM exceeded the US Market which returned 5.9% over the past year.


Shareholder returns

AXSMIndustryMarket
7 Day15.8%-0.1%1.3%
30 Day-29.3%-0.7%-1.9%
90 Day-18.5%-2.7%-1.8%
1 Year426.3%426.3%-4.3%-6.6%8.3%5.9%
3 Year190.2%190.2%16.9%8.6%45.6%36.2%
5 Yearn/a27.3%13.9%66.1%47.9%

Price Volatility Vs. Market

How volatile is Axsome Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Axsome Therapeutics undervalued compared to its fair value and its price relative to the market?

29.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate AXSM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate AXSM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXSM is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: AXSM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate AXSM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXSM is overvalued based on its PB Ratio (29.2x) compared to the US Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is Axsome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

52.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXSM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXSM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXSM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AXSM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AXSM's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if AXSM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Axsome Therapeutics performed over the past 5 years?

-30.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AXSM is unprofitable, and losses have increased over the past 5 years at a rate of -30.9% per year.

Accelerating Growth: Unable to compare AXSM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXSM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: AXSM has a negative Return on Equity (-174.12%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AXSM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AXSM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Axsome Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AXSM's short term assets ($54.6M) exceeds its short term liabilities ($13.1M)

Long Term Liabilities: AXSM's short term assets (54.6M) exceeds its long term liabilities (17.4M)


Debt to Equity History and Analysis

Debt Level: AXSM's debt to equity ratio (80.6%) is considered high

Reducing Debt: AXSM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: AXSM has a low level of unsold assets or inventory.

Debt Coverage by Assets: AXSM's debt is covered by short term assets (assets are 2.786960x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXSM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXSM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21.4% each year


Next Steps

Dividend

What is Axsome Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AXSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXSM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AXSM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXSM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Axsome Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Herriot Tabuteau (51yo)

7.8yrs

Tenure

US$1,057,425

Compensation

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer and Chairman since January 2012. Dr. Tabuteau serves as President at Axsome Therapeutics, ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Herriot's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Herriot's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.1yrs

Average Tenure

44yo

Average Age

Experienced Management: AXSM's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

51yo

Average Age

Experienced Board: AXSM's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: AXSM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$54,06430 Sep 19
Nick Pizzie
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares2,180
Max PriceUS$24.80
BuyUS$374,28027 Jun 19
Mark Coleman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares16,200
Max PriceUS$23.25
BuyUS$39,93612 Jun 19
Nick Pizzie
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares1,920
Max PriceUS$20.80
BuyUS$78,15524 May 19
Mark Saad
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,500
Max PriceUS$22.33
BuyUS$99,69615 May 19
Mark Coleman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,650
Max PriceUS$21.44
BuyUS$67,93921 Mar 19
Nick Pizzie
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares5,400
Max PriceUS$12.69
BuyUS$62,11821 Mar 19
Mark Coleman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,100
Max PriceUS$12.18

Ownership Breakdown


Management Team

  • Herriot Tabuteau (51yo)

    Founder

    • Tenure: 7.8yrs
    • Compensation: US$1.06m
  • Dave Marek (54yo)

    Chief Commercial Officer

    • Tenure: 0.2yrs
  • Mark Jacobson (36yo)

    Senior Vice President of Operations & Secretary

    • Tenure: 4yrs
  • Cedric O'Gorman (44yo)

    Senior Vice President of Clinical Development & Medical Affairs

    • Tenure: 2.1yrs
  • Nick Pizzie (44yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.4yrs
    • Compensation: US$687.98k
  • Joseph Debrah-Afful

    Director of Finance

    • Tenure: 0yrs

Board Members

  • Roger Jeffs (57yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$99.38k
  • Myrtle Potter (61yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$94.56k
  • Mark Saad (49yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$88.38k
  • Herriot Tabuteau (51yo)

    Founder

    • Tenure: 7.8yrs
    • Compensation: US$1.06m
  • Mark Coleman (51yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$80.88k

Company Information

Axsome Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Axsome Therapeutics, Inc.
  • Ticker: AXSM
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$710.055m
  • Shares outstanding: 34.42m
  • Website: https://www.axsome.com

Number of Employees


Location

  • Axsome Therapeutics, Inc.
  • 200 Broadway
  • 3rd Floor
  • New York
  • New York
  • 10038
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXSMNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2015
19XDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2015
0HKFLSE (London Stock Exchange)YesCommon StockGBUSDNov 2015

Biography

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes A ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:37
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.